Skip to content

Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain

Investigational Plan for the Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02293525
Enrollment
0
Registered
2014-11-18
Start date
Unknown
Completion date
2016-01-31
Last updated
2016-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Brief summary

The purpose of this study is to evaluate the clinical performance of the ReLeaf infusion catheter & wound drain in patients following lumbar spinal fusion surgery. One half of the patients will receive continuous local analgesic fusion during the post-operative period while the other half will received continuous local saline.

Detailed description

Posterior lumbar spinal fusion is commonly used in the management of a wide array of spinal disorders ranging from instability to degenerative disc disease. However, severe postoperative pain is a significant adverse outcome in patients who have undergone a lumbar spinal fusion procedure. This pain may delay mobilization and decrease compliance with physical, occupational, or pulmonary physiotherapy. Pain symptoms may worsen with activity and ambulation due to reflex spasms of the paraspinal muscles elicited by pain from the wound. A local anesthetic agent administered immediately after surgery into the tissue surrounding the wound addresses the pain source for less than four hours. Therefore, it is reasonable to consider continuous local anesthetic infusion, which may limit local pain mediators for a longer duration. Continuous local anesthetic infusion into the paraspinal musculature with the ReLeaf catheter has the potential to reduce pain, narcotic demand & usage, and accelerate the rate of recovery in lumbar spinal fusion patients.

Interventions

DEVICEReLeaf catheter

Continuous infusion rate 10ml/hr (5ml/side)

DRUGRopivacaine
DRUGSaline
DRUGMorphine

Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg

DRUGOxycodone

10mg every 4-6 hours

Sponsors

Vital 5, LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Skeletally mature * Diagnosis of lumbar spine disease requiring an open, midline, instrumented posterolateral fusion with or without interbody support at one or two vertebral levels and laminectomy or laminotomy * Physically and mentally willing to comply with the study requirements * Signed the study informed consent

Exclusion criteria

* Lumbar spine disease requiring more than two levels of instrumentation * Any previous operative lumbar procedure, except discectomy or hemi-laminotomy performed a minimum of 2 years prior to current study surgery * Patients requiring iliac crest bone graft for the procedure * Intra-operative durotomy * Any duration of pre-operative morphine or morphine equivalent use exceeding 30 mg of morphine equivalents per day for longer than 3 months * Physically or mentally compromised (i.e., being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease, presence of alcohol or substance abuse) * Diagnosed with Severe Depression and on treatment * Active infection at the operative level or a symptomatic infection * Diagnosed systemic disease that would affect the subject's welfare or overall outcome of the research study (i.e. Paget's disease, renal osteodystrophy, Lupus etc) * Is pregnant or breast feeding * Has any active malignancy or spinal arthrodesis being performed for a tumor decompression * Has a known allergy to local analgesics * Pending litigation related to back pain or injury or Worker's Compensation

Design outcomes

Primary

MeasureTime frameDescription
Pain (Mean VAS pain score at 24 hours post-procedure)24 hoursMean VAS pain score at 24 hours post-procedure

Secondary

MeasureTime frameDescription
Medication Use3 monthsNarcotic use from surgery through 3 months post-operative
Adverse Events3 monthsOccurrence of adverse events through 3 months post-operative

Other

MeasureTime frameDescription
Time of Foley Catheter RemovalDischarge, on average 2 to 3 daysTime foley catheter was removed following surgery but no later than hospital discharge (which is 2-3 days on average)
Length of Hospital StayDischarge, on average 2 to 3 daysTime from surgery to hospital discharge, on average 2 to 3 days
Time to First AmbulateDischarge, on average 2 to 3 daysTime to walk following surgery but no later than hospital discharge (which is 2-3 days on average)
Incisional Pain3 monthsPain at the site of the incision at 3 months post-operative
Incidence of nausea and vomitingDischarge, on average 2 to 3 daysOccurrence of nausea with or without vomiting and treatments from time of surgery through hospital discharge (which is 2-3 days on average)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026